11. https://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/An-Open- label-Multicohort-Phase-1-2-Study-in-Patients-With-Virus-Associated-Cancers- CheckMate-358-Safety-and-Efficacy-of-Neoadjuvant-Nivolumab-in-Squamous-Cell- Carcinoma-of-the-Head-and-Neck-SCCHN . 12. Knudson KM, Hicks KC, Luo X, Chen JQ, Schlom J, Gameiro SR: M7824, a novel bifunctional anti-PD-L1/TGFbeta Trap fusion protein, promotes anti-tumor efficacy 84 Abbreviated Title: Neoadjuvant IO for HNSCC Version Date: August 31, 2022 as monotherapy and in combination with vaccine . Oncoimmunology 2018, 7(5):e1426519.